|
1）Berk T, Gordon SJ, Choi HY, et al. Cyto-megalovirus infection of the colon: a possible role in exacerbations of inflammatory bowel disease. Am J Gastroenterol. 1985; 80(5): 355-60
|
|
|
|
2）Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohns colitis. Am J Gastroenterol. 2001; 96(3): 773-5
|
|
|
|
|
3）Vega R, Bertran X, Menacho M, et al. Cyto-megalovirus infection in patients with inflam-matory bowel disease. Am J Gastroenterol. 1999; 94(4): 1053-6
|
|
|
|
|
|
4）Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in trans-plant recipients. Clin Infect Dis. 2002; 34(8): 1094-7
|
|
|
|
|
|
5）Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cyto-megalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997; 100(12): 3154-63
|
|
|
|
|
|
6）Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immuno-suppressive therapies. Inflamm Bowel Dis. 2007; 13(12): 1516-21
|
|
|
|
|
|
7）Roblin X, Pillet S, Oussalah A, et al. Cytomegalo-virus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011; 106(11): 2001-8
|
|
|
|
|
|
8）Matsuoka K, Iwao Y, Mori T, et al. Cytomega-lovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007; 102(2): 331-7
|
|
|
|
|
|
9）Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010; 16(9): 1620-7
|
|
|
|
|
|
10）Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009; 3(2): 47-91
|
|
|
|
|
|
11）Kim YS, Kim Y-H, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastro-enterol. 2012; 46(1): 51-6
|
|
|
|
|
|
12）Musa S, Thomson S, Cowan M, et al. Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol. 2010; 45(3): 261-72
|
|
|
|
|
|
13）Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5(3): 345-51.
|
|
|
|
|
|
14）Kaneko T, Matsuda R, Taguri M, et al. Clostridium difficile infection in patients with ulcerative colitis: investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol. 2011; 35(4): 315-20
|
|
|
|
|
|
15）Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008; 57(2): 205-10
|
|
|
|
|
|
16）Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103(6): 1443-50
|
|
|
|
|
|
17）Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009; 104(5): 1162-9
|
|
|
|
|
|
18）Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010; 4(2): 194-8
|
|
|
|
|
|
19）Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an under-appreciated and increasing cause of death and complications. Ann Surg. 2002; 235(3): 363-72
|
|
|
|
|